Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Obinutuzumab in Treatment Naive CLL
NCT04505254Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Treatment-free remission up to 4 years and Overall response rate up to 4 years. Started Aug 2020; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04505254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505254.